OncoMatch/Clinical Trials/NCT06311578
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Is NCT06311578 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including JNJ-87704916 and Cetrelimab for neoplasms.
Treatment: JNJ-87704916 · Cetrelimab — The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage IV, III
metastatic or locally advanced NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all available standard of care therapy
advanced or metastatic solid tumor exhausting all available standard of care therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NYU Langone Health · New York, New York
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
- UPMC Cancer Centers · Pittsburgh, Pennsylvania
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify